Ziftomenib Maintenance Post Allo-HCT

This study tests ziftomenib — a targeted drug — as maintenance therapy for people with acute myeloid leukemia (AML, a type of blood cancer) who have received a bone marrow transplant and are currently in remission. The goal is to help prevent the cancer from coming back. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with AML (a blood cancer) - You are in complete remission (no detectable cancer) after a bone marrow/stem cell transplant from a donor - You carry a specific gene change called NPM1 mutation or KMT2A rearrangement in your cancer cells **You may NOT be eligible if...** - Your cancer has returned after the transplant - You are experiencing serious transplant complications (like graft-versus-host disease) that need active treatment - You have significant heart, liver, or kidney problems - You are on medications that strongly interfere with how the study drug works Talk to your doctor to see if this trial is right for you.